Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) Shares Outstanding (Diluted Average): 2023-2025

Historic Shares Outstanding (Diluted Average) for Camp4 Therapeutics (CAMP) over the last 2 years, with Sep 2025 value amounting to $27.3 million.

  • Camp4 Therapeutics' Shares Outstanding (Diluted Average) rose 4792.88% to $27.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.3 million, marking a year-over-year increase of 4792.88%. This contributed to the annual value of $4.7 million for FY2024, which is 1087.44% up from last year.
  • Latest data reveals that Camp4 Therapeutics reported Shares Outstanding (Diluted Average) of $27.3 million as of Q3 2025, which was up 35.29% from $20.2 million recorded in Q2 2025.
  • Camp4 Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $27.3 million for Q3 2025, and its period low was $394,976 during Q4 2023.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $557,437 (2024), whereas its average is $8.3 million.
  • Data for Camp4 Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY soared of 4,792.88% (in 2025) over the last 5 years.
  • Over the past 3 years, Camp4 Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $394,976 in 2023, then skyrocketed by 1,087.44% to $4.7 million in 2024, then spiked by 4,792.88% to $27.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $27.3 million for Q3 2025, versus $20.2 million for Q2 2025 and $20.2 million for Q1 2025.